Ritonavir
Ritonavir. HIV-1 protease inhibitor; modern use is as a PK booster (CYP3A4 inhibitor) for other PIs and Paxlovid. Most potent oral CYP3A4… Oral half-life 4 h.
HIV-1 protease inhibitor; modern use is as a PK booster (CYP3A4 inhibitor) for other PIs and Paxlovid. Most potent oral CYP3A4 inhibitor available. Major DDI source — extensive contraindication list (statins, ergots, sedatives, alpha-blockers).
INTERACTIONS: THE ONE BLOCK THAT DELIBERATELY USES TWO ASSUMED CONCENTRATIONS, AND IT IS RIGHT TO. Its notes distinguish full-dose ritonavir from the 100 mg BOOSTER dose and calibrate each edge to the regimen its own source studied — 5 µM for the former, 1.5 µM for the latter. Those are genuinely different exposures of the same drug, so a single block constant would have been the cruder choice; the per-edge field now records the distinction that the prose was carrying alone. THREE EDGES REFUSE TO RECONSTRUCT AND ARE LEFT ALONE: simvastatin, tacrolimus and midazolam cite 32-fold, 57-fold and 28-fold rises while their stored values imply roughly 20, 36 and 46. THESE ARE THE THREE LARGEST FOLD-CHANGES IN THE BLOCK, and the same is true of the unreconstructed edges on itraconazole — but two are attenuated and one is amplified, so the pattern is real and its cause is not established.
Related compounds
- Atorvastatin — major
- Simvastatin — contraindicated
- Tacrolimus — contraindicated
- Midazolam — contraindicated
- Sildenafil — contraindicated
- Alprazolam — major
- Fentanyl — major
- Amlodipine — warn
Sources: PMID:10930961, PMID:10801241, PMID:10485779, PMID:33452585